Intellia amends bylaws to adopt majority voting for uncontested director elections

Intellia Therapeutics, Inc.

Majority vote standard adopted for uncontested director elections; plurality retained for contested elections.
Amended bylaws include proxy solicitation procedures consistent with SEC Rule 14a-19.
Changes effective April 3, 2025; Board approved on recommendation of governance committee.
Other clarifying and procedural amendments also made to the bylaws.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Intellia Therapeutics, Inc.: Amended and restated bylaws to adopt majority vote standard in uncontested elections, implement proxy solicitation procedures consistent with Rule 14a-19, and make clarifying changes (effective 2025-04-03).

Change: bylaw amendment
Effective: 2025-04-03

Exact text from the filing

On April 3, 2025, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted and approved the amendment and restatement of the Company’s Second Amended and Restated By-laws in their entirety, effective as of April 3, 2025.

View on SEC.gov

Browse all governance changes →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-073904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.